Business Context and Reporting Period
This Form 8-K Current Report was filed by InMed Pharmaceuticals Inc. on September 17, 2024. The Company, incorporated in British Columbia and listed on the Nasdaq Capital Market under the symbol "INM," is reporting a material event regarding its continued listing status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Delisting Notice: On September 17, 2024, the Nasdaq Staff issued a determination that the Company failed to satisfy the Minimum Bid Price Rule (Nasdaq Listing Rule 5550(a)(2)) by the end of its extended compliance period on September 16, 2024.
- Compliance History: The Company initially received a notification on September 19, 2023, regarding non-compliance with the $1.00 minimum bid price requirement. An additional 180-day compliance period was granted on March 19, 2024, which expired without the Company regaining compliance.
- Appeal Filed: The Company has timely requested a hearing before the Nasdaq Listing Qualifications Panel to appeal the delisting determination.
Outlook, Risks, and Management Commentary
- Stay of Delisting: The filing of the appeal has stayed any delisting or suspension action pending the Panel's final decision.
- Hearing Schedule: The appeal hearing is scheduled for October 31, 2024.
- Panel Discretion: The Panel has the authority to grant up to an additional 180 calendar days to regain compliance, apply more stringent criteria, or proceed with delisting.
- Risk Factors: Management explicitly states there is no guarantee that the Panel will grant an extension or that the appeal outcome will be favorable. The Company faces the risk of suspension or delisting, including the potential filing of a Form 25-NSE.
Investor Verification Checklist
- Verify the current trading status of INM shares on the Nasdaq Capital Market.
- Monitor the outcome of the Nasdaq Listing Qualifications Panel hearing scheduled for October 31, 2024.
- Review the Company's plan to regain and sustain compliance with the $1.00 minimum bid price rule, as presented in the appeal.
- Check for any subsequent press releases or filings regarding the Panel's final decision.